← All candidates
No insider filings on record.
Nothing on file yet.
NAMSNewAmsterdam Pharma Co N.V.
NasdaqGM · Healthcare · $2.56B
$21.18
+0.09% · Sep 16
No insider filings on record.
NewAmsterdam Pharma Co N.V. hasn't reported Form 4 activity yet.
Price · 1Y · dailyNo open-market activity in range
▸ hover a marker for the filing · drag to zoom · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$2.56B
Float
82.9M
71% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
359.7
The record
newest first
No insider transactions on file for NAMS yet.
Context
Earnings · EPS vs forecast
1 of 4 quarters beat
Q2 '26−$0.45 act−$0.02
Q1 '26−$0.34 act+$0.07
Q4 '25−$0.53 act−$0.17
Q3 '25−$0.53 act−$0.19
Coverage
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim NearsMarketBeat · 08-05NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue EstimatesZacks · 08-05A Look At NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price WeaknessSimply Wall St. · 06-11NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesSimply Wall St. · 05-11
The file stays open
Nothing on file yet.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice